BSF Enterprise PLC Publication of New Research (2225B)

TIDMBSFA

RNS Number : 2225B

BSF Enterprise PLC

01 June 2023

1 June 2023

BSF Enterprise PLC

("BSF" or the "Company")

Publication of New Research

BSF (LSE: BSFA; OTCQB: BSFAF), the Main Market listed biotech company and the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to inform shareholders that a new research note on the Company has recently been published by Shard Capital Partners LLP.

The note can be found on the Company's website, www.bsfenterprise.com , or via the Shard Portal .

-Ends-

   For further enquiries, please visit   www.bsfenterprise.com   or contact: 
 
 
 
   BSF Enterprise PLC                          Via SEC Newgate 
                                               below 
 Che Connon - CEO & Executive 
  Director 
  Geoff Baker - Executive Director 
 
 
   Shard Capital (Broker) 
 Damon Heath                                 0203 971 7000 
  Isabella Pierre                             0207 1869 927 
 
 
   SEC Newgate (Financial Communications) 
 Bob Huxford                                 020 3757 6882 
  Elisabeth Cowell                            [e-mail] 
  George Esmond 
 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it has produced the UK's first high quality lab-grown meat from its laboratory using its technology.

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as acquiring complementary businesses. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DOCEFLFXXELFBBV

(END) Dow Jones Newswires

June 01, 2023 02:00 ET (06:00 GMT)